[go: up one dir, main page]

TN2015000168A1 - Inhibiteurs de la tyrosine kinase de bruton - Google Patents

Inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
TN2015000168A1
TN2015000168A1 TNP2015000168A TN2015000168A TN2015000168A1 TN 2015000168 A1 TN2015000168 A1 TN 2015000168A1 TN P2015000168 A TNP2015000168 A TN P2015000168A TN 2015000168 A TN2015000168 A TN 2015000168A TN 2015000168 A1 TN2015000168 A1 TN 2015000168A1
Authority
TN
Tunisia
Prior art keywords
tyrosine kinase
inhibitors
compounds
disclosed
conditions
Prior art date
Application number
TNP2015000168A
Other languages
English (en)
Inventor
John Robert Springer
Balekudru Devadas
Danny James Garland
Margaret Lanahan Grapperhaus
Seungil Han
Susan Landis Hockerman
Robert Owen Hughes
Eddine Saiah
Mark Edward Schnute
Shaun Raj Selness
Daniel Patrick Walker
Zhao-Kui Wan
Li Xing
Christoph Wolfgang Zapf
Michelle Ann Schmidt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TN2015000168A1 publication Critical patent/TN2015000168A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il est divulgué dans le présent mémoire des composés qui forment des liaisons covalentes avec la tyrosine-kinase de Bruton (BTK) . Des procédés pour la préparation des composés sont divulgués. Il est également divulgué des compositions pharmaceutiques qui comprennent les composés. Il est divulgué des procédés d'utilisation des inhibiteurs de BTK, seuls ou en association avec d'autres agents thérapeutiques, pour le traitement de maladies ou affections auto-immunes, de maladies ou affections hétéroimmunes,d'un cancer, y compris d'un lymphome, et de maladies ou d'affections inflammatoires. (Formule I) .
TNP2015000168A 2012-11-02 2015-04-30 Inhibiteurs de la tyrosine kinase de bruton TN2015000168A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04
PCT/IB2013/059846 WO2014068527A1 (fr) 2012-11-02 2013-11-01 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
TN2015000168A1 true TN2015000168A1 (fr) 2016-10-03

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000168A TN2015000168A1 (fr) 2012-11-02 2015-04-30 Inhibiteurs de la tyrosine kinase de bruton

Country Status (27)

Country Link
US (4) US20150291554A1 (fr)
EP (1) EP2914586B1 (fr)
JP (1) JP6178861B2 (fr)
KR (1) KR101668574B1 (fr)
CN (1) CN105008344B (fr)
AP (1) AP2015008381A0 (fr)
AU (1) AU2013340345B2 (fr)
BR (1) BR112015009624A2 (fr)
CA (1) CA2888960C (fr)
CL (1) CL2015001168A1 (fr)
CO (1) CO7350624A2 (fr)
CR (1) CR20150228A (fr)
DO (1) DOP2015000100A (fr)
EA (1) EA201500393A1 (fr)
ES (1) ES2625944T3 (fr)
GE (1) GEP201606597B (fr)
HK (1) HK1211293A1 (fr)
IL (1) IL238571A0 (fr)
MD (1) MD20150035A2 (fr)
MX (1) MX2015005422A (fr)
NI (1) NI201500059A (fr)
PE (1) PE20151070A1 (fr)
PH (1) PH12015500940A1 (fr)
SG (1) SG11201502893WA (fr)
TN (1) TN2015000168A1 (fr)
TW (1) TWI518080B (fr)
WO (1) WO2014068527A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045813A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970163B1 (fr) 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH Dérivés de 5-thiazolecarboxamide et leur utilisation en tant qu'inhibiteurs de la btk
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CN112608298A (zh) * 2013-03-15 2021-04-06 詹森药业有限公司 用于制备药物的方法和中间体
WO2014152114A1 (fr) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Composés hétéroaromatiques en tant qu'inhibiteurs de btk
IL299897B2 (en) 2013-08-19 2024-02-01 Taris Biomedical Llc Devices and methods for administering multiple units of drug
MX2016004030A (es) * 2013-09-30 2016-10-26 Beijing Synercare Pharma Tech Co Ltd Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
WO2015116485A1 (fr) * 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Composés de pyrazole utilisés en tant qu'inhibiteurs de btk
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
WO2015185998A2 (fr) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016019237A2 (fr) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CA2970723C (fr) 2014-12-18 2023-09-05 Principia Biopharma Inc. Traitement du pemphigus
WO2016192074A1 (fr) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Inhibiteurs de la btk
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
HK1258779A1 (zh) 2015-09-16 2019-11-22 Loxo Oncology Inc. 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
CN108884076B (zh) * 2015-11-17 2021-07-30 默克专利有限公司 使用具有btk抑制活性的嘧啶和吡啶化合物治疗多发性硬化症的方法
SI3390395T1 (sl) * 2015-12-16 2020-11-30 Loxo Oncology, Inc. Spojine uporabne kot inhibitorji kinaz
CA3005268C (fr) 2015-12-16 2024-04-30 Boehringer Ingelheim International Gmbh Composes heteroaromatiques utilises en tant qu'inhibiteurs de la btk
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
JP6953445B2 (ja) * 2016-05-16 2021-10-27 スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドＳｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｂｔｋ阻害剤としての５−アミノピラゾールカルボキサミド誘導体およびその製造方法および医薬組成物
JP7129704B2 (ja) 2016-06-29 2022-09-02 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペント－２－エネニトリルの放出調節製剤
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018102785A2 (fr) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
MX2020003671A (es) 2017-10-06 2020-08-03 Forma Therapeutics Inc Inhibicion de peptidasa especifica de ubiquitina 30.
WO2019091441A1 (fr) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 Composé 5-amino pyrazole carboxamide en tant qu'inhibiteur de btk et son procédé de préparation
WO2019091438A1 (fr) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 Dispersion solide amorphe d'un composé de 5-aminopyrazole carboxamide comme inhibiteur de btk
CN111225669B (zh) * 2017-11-10 2020-12-29 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
KR102533599B1 (ko) * 2019-03-14 2023-05-17 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN120136774A (zh) * 2019-05-21 2025-06-13 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
WO2021076514A1 (fr) 2019-10-14 2021-04-22 Principia Biopharma Inc. Procédé de traitement de la thrombocytopénie immunitaire par l'administration de (r)-2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyle]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021150723A1 (fr) 2020-01-22 2021-07-29 Principia Biopharma Inc. Formes cristallines de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényle) -1h-pyrazolo [3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4- (oxétane-3-yl)) pipérazine-1-yl] pent-2-enenitrile
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
MX2023002953A (es) * 2020-09-11 2023-06-01 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
WO2022140246A1 (fr) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Procédés et composés destinés à l'autophagie ciblée
WO2023284765A1 (fr) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 Composé pyrazole substitué, composition le contenant et son utilisation
CN116554102B (zh) * 2022-01-28 2025-10-03 深圳海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法和应用
CA3243695A1 (fr) * 2022-02-04 2023-08-10 Retune Pharma Inc Certaines entités chimiques, compositions et procédés
WO2024153226A1 (fr) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 Composé cyclique fusionné au pyrazole, composition pharmaceutique et utilisation de celui-ci
WO2024153237A1 (fr) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 Inhibiteurs de tyrosine kinase igf-1r, composition pharmaceutique et leur utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EP1436265A4 (fr) * 2001-09-27 2004-12-15 Smithkline Beecham Corp Composes chimiques
AU2007235237B2 (en) * 2006-04-11 2011-08-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
PL2529622T3 (pl) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
EP2173728A2 (fr) * 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
CN102159214A (zh) * 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
US8785440B2 (en) * 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
US8685969B2 (en) * 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US20140045813A1 (en) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN115155188A (zh) 2014-04-09 2022-10-11 唐纳森公司 自承式折叠的片材材料以及过滤元件
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
PE20151070A1 (es) 2015-08-01
ES2625944T3 (es) 2017-07-21
MD20150035A2 (ro) 2015-10-31
WO2014068527A1 (fr) 2014-05-08
US10266513B2 (en) 2019-04-23
SG11201502893WA (en) 2015-05-28
CN105008344B (zh) 2017-07-25
AU2013340345A1 (en) 2015-04-30
NI201500059A (es) 2015-06-05
CR20150228A (es) 2015-09-14
CO7350624A2 (es) 2015-08-10
EP2914586A1 (fr) 2015-09-09
IL238571A0 (en) 2015-06-30
JP2015535277A (ja) 2015-12-10
KR20150075114A (ko) 2015-07-02
CA2888960A1 (fr) 2014-05-08
CL2015001168A1 (es) 2015-07-10
JP6178861B2 (ja) 2017-08-09
US20190202798A1 (en) 2019-07-04
TWI518080B (zh) 2016-01-21
PH12015500940A1 (en) 2015-06-29
TW201431851A (zh) 2014-08-16
CA2888960C (fr) 2017-08-15
GEP201606597B (en) 2017-01-10
BR112015009624A2 (pt) 2017-11-14
US20170283393A1 (en) 2017-10-05
EA201500393A1 (ru) 2016-05-31
KR101668574B1 (ko) 2016-10-24
EP2914586B1 (fr) 2017-04-05
US20150291554A1 (en) 2015-10-15
DOP2015000100A (es) 2015-12-31
AU2013340345B2 (en) 2016-10-27
HK1211293A1 (en) 2016-05-20
AP2015008381A0 (en) 2015-04-30
US10815213B2 (en) 2020-10-27
MX2015005422A (es) 2015-08-05
US20210002251A1 (en) 2021-01-07
CN105008344A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA38961A1 (fr) Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
MA38056A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses